Introduction
Ovarian cancer (OC) is the fifth most common cause of cancer-related deaths among women, with ~90% of these cases being epithelial ovarian cancer (EOC). 1 At the start of 2018, there were an estimated 22,240 newly diagnosed cases and 14,070 deaths due to OC in USA. 1 Although OC is less common than other cancers such as breast cancer, OC is attracting increased attention because of its poor prognosis. The 5-year survival rate for OC is only 47.2%. Although great progress has been made in cancer research, the overall prognosis for OC remains poor, because it is often diagnosed late in the disease process and has high recurrence rates after curative resection. 2 Therefore, more effective and convenient markers must be identified to estimate the prognosis and select appropriate treatment strategies.
Over the past decades, many theories have been postulated to explain OC's etiology, and most of them converge on the role of inflammation. 3 The systemic inflammatory response is associated with survival in advanced and localized cancers. 4 Cancer-related inflammation includes modulating inflammatory cells and mediators such as cytokines
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gao et al and chemokines; however, these markers are not routinely measured despite their direct changes provide a direct surrogate marker of expression (eg, lymphocyte-to-monocyte ratio [LMR] ). 4 Several recent studies assessed the prognostic effect of pretreatment LMR among patients with OC, but the results were inconsistent. Elevated LMR was shown to increase survival in some, [5] [6] [7] but not all, [8] [9] [10] [11] studies. As the statistical power of an individual study may be too weak to identify associations between pretreatment LMR and OC patient survival (sample size of most included studies was <300 OC patients), a meta-analysis combining data from all published studies may be more convincing.
Thus, we conducted a meta-analysis to evaluate the prognostic effect of pretreatment LMR on OC patient survival, which included all eligible publications to date.
Materials and methods
This meta-analysis was conducted in accordance with the PRISMA (Table S1) . 12 
search strategies
A comprehensive literature search of PubMed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI, http://www.cnki.net), and the Wanfang databases (http://www.wanfangdata.com.cn) was conducted from inception through October 2018. The following search terms were used: (lymphocyte-to-monocyte or lymphocyte monocyte or lymphocyte-monocyte or lymphocyte to monocyte or lymphocyte/monocyte or LMR) AND (cancer* or carcinoma* or neoplasm* or malignan* or tumour* or tumor*) AND (ovary or ovarian) without language restriction (Supplementary materials). Related articles generated by Google Scholar (http://scholar.google.com) and PubMed were retrieved. We also scanned the reference lists of related articles to identify all potential useful studies on OC that might have been missed in our database searches.
study selection
Inclusion criteria were as follows: 1) studies on patients with OC diagnosed histopathologically; 2) studies that assessed the prognostic value of pretreatment LMR among OC patients; 3) studies that reported the LMR cutoff value; 4) studies that reported sufficient information for calculating the HR and its 95% CI; and 5) studies that used overall survival (OS) and/or progression-free survival (PFS) as outcomes. For studies with overlapping data, only the most relevant articles with the largest datasets were included in the final analysis.
Data extraction
Two independent reviewers (X-PG and Y-HL) evaluated all potential articles for inclusion. Disagreements were resolved by discussion among all coauthors. The following information was collected: the first author's name, publication year, country (region) and ethnicity of the population, publication type, number of OC patients at baseline, age, year of recruitment, time of follow-up, treatment method, tumor stage, histological type, LMR cutoff value, method of obtaining cutoff value, OC diagnostic criteria, survival analysis methods, and prognostic end points (OS or PFS). HRs were extracted from multivariate or univariate analyses or Kaplan-Meier survival curves. If only Kaplan-Meier curves were provided, we extracted data from the survival curves using Engauge Digitizer v.4.1 software. 13 
Quality assessment
Each study's methodological quality was assessed as per the Newcastle-Ottawa Scale (NOS), 14 which was used to allocate a maximum of nine stars for selection quality of the study population, comparability, and outcome. The studies' quality scores ranged from 0 to 9, with 7-9 points indicating a highquality study and 0-6 points indicating a low-quality study.
statistical analyses
The DerSimonian and Laird random-effects model of inverse variance methods was used to estimate the pooled HRs and 95% CIs. Unless otherwise stated, we used the most fully adjusted RRs from each study, and the low LMR group was treated as the reference group. If the studies used different reference groups to estimate the LMR HR for OS/PFS, we used an Excel macro file to transform the reference group. 15 The random-effects model was chosen a priori, because it is considered to be more conservative than the fixed-effects model and it accounts for both within-and between-study heterogeneity. 16 Between-study heterogeneity was tested using Cochran's Q test and Higgins I 2 statistic (higher I 2 values denote greater heterogeneity). 17 We performed subgroup analyses for both OS and PFS to examine the robustness of the results by age (<55 vs ≥55 years), LMR cutoff value (≤3.0 vs >3.0), sample size (≤200 vs >200), and NOS score (<7 and ≥7 points). Influence analysis was also conducted to assess the effect of a single study on the pooled estimates. 18 These variables were also analyzed as covariates in the meta-regression analysis. Publication bias was assessed by visually inspecting funnel plots and quantitatively evaluated using Egger's and Begg's linear regression asymmetry tests. 17 All data were analyzed using Stata software, version 11. 
Results
search results
The electronic database searches identified 1,018 articles (Figure 1 ), of which 180 duplications were excluded by Endnote. After assessing titles and abstracts and screening full texts, 824 unrelated articles were excluded. For the remaining 14 potentially eligible articles, 2 duplicate studies, 1 duplicate study, 19 and 1 study with incomplete data 20 were further excluded. Finally, 12 studies were included. [5] [6] [7] [8] [9] [10] [11] [21] [22] [23] [24] [25] Characteristics of the included studies (Table  S2 ). Most cases were EOC, and 76.5% were stage III/IV. Among these studies, three investigated only OS, while nine investigated both OS and PFS. 2 =76.5%; Table 2 and Figure  2A ). The association persisted after reanalyzing studies among Asian patients or those with only EOC. Stratified analyses for age, LMR cutoff values, sample size, and NOS score revealed significant interactions for age (P for interaction =0.017) and LMR cutoff values (P for interaction =0.025). The protective effect of elevated LMR was more evident among younger patients than older patients (HR: 2.28 vs 1.47) and among studies using an LMR cutoff of >3.0 than in those using ≤3.0 (HR: 2.09 vs 1.38). Meta-regression analysis further confirmed that age, but not LMR cutoff values, significantly contributed to inter-study heterogeneity (P for regression =0.004 and 0.153; Table S3 ).
association between lMR and PFs in OC patients
Eight studies 5-9,21,23,25 involving 2,114 patients reported data for the association between LMR and PFS among OC patients, and all studies were conducted among Asian patients. Similar to OS, the random-effects combined analysis demonstrated that LMR was positively and significantly associated with PFS (pooled HR: 1.70, 95% CI: 1.49-1.94, P<0.001) but with low between-study heterogeneity (I 2 =24.4%; P=0.234; Table 2 and Figure 2B ). The result was similar among studies with only EOC cases. Stratified analyses suggested that the association did not differ among NOS scores, LMR cutoff values, and age strata (P interaction range =0.066-0.987). Meta-regression analysis also revealed that publication year, age, NOS score, sample size, and LMR cutoff value did not significantly contribute to heterogeneity (P for regression range =0.086-0.982).
sensitivity analysis and bias
The sensitivity analyses indicated that the pooled HRs were not obviously influenced by any single study for either OS or PFS (Table 2) . Both Egger's and Begg's tests revealed no significant publication bias, and the P-values were 0.732 and 0.272 for OS and 1.000 and 0.887 for PFS. The funnel plots also showed no evidence of publication bias for either OS or PFS (Figure 3 ). 
Discussion
In this meta-analysis, we first report the prognostic value of pretreatment LMR among OC patients. Our results indicate that higher pretreatment LMR levels are associated with increased OS and PFS among OC patients. Substantial heterogeneity was observed for OS; further subgroup and meta-regression analyses indicated that age contributed to this heterogeneity, and these associations were more evident among younger patients than older populations. In recent years, several prognostic indicators derived from peripheral blood, such as LMR, have been widely investigated as useful prognostic markers in cancers. LMR has been identified as an independent prognostic factor in patients with various cancers, such as head and neck, 26 pancreatic, 27 colorectal, 28 hepatocellular, 29 and breast cancers. 30 Our results were consistent with findings from these studies, showing that higher LMR ratios may improve cancer prognoses.
The exact mechanisms by which LMR has some prognostic relevance in OC patients were still unknown. According to the current evidence, lymphopenia might weaken the efficacy of the immune system and be associated with worse prognosis in cancers; cell-mediated cytotoxicity may e Influence analysis was conducted by eliminating one study at a time; for OS, the excluded study was the study by Tang et al 22 for minimal pooled RRs, and li et al 10 for the maximal pooled RRs; for PFs, the excluded study was the study by Zhang et al 5 for minimal pooled RRs, and Tian 23 for the maximal pooled RR. Abbreviations: eOC, epithelial ovarian cancer; lMR, lymphocyte-to-monocyte ratio; nOs, newcastle-Ottawa scale; OC, ovarian cancer; Os, overall survival; PFs, progression-free survival.
be attenuated if the level of effector T cells is insufficient. 31 Circulating monocytes may contribute to both tumor growth and reduced immunosurveillance through differentiating into macrophages after infiltrating a tumor and then respond to the wide spectrum of chemokines and growth or differentiation factors. 31 Thus, the prognostic effect of LMR among OC patients can be assumed to be related to tumor-infiltrating immune cells, such as tumor-infiltrating lymphocytes (TILs), or tumor-associated macrophages. Circulating TILs, as direct measures of intratumoral immunity, may contribute to cancer growth and spread. 32 In OC tumor tissue sections, intraepithelial CD8+ TILs correlated with good outcome, and a high ratio of CD8+/FoxP3+ T regulatory cells was beneficial to survival. 33 Recent epidemiological studies have also confirmed that the presence of TILs was associated with improved clinical outcomes in OC patients. [34] [35] [36] Peripheral blood-based parameters (eg, LMR) have been studied as a surrogate measures of intratumoral immunity that reflect a host's immune response. 4 LMR has been shown a statistically significant correlation with CD8+ TILs among patients with breast cancer. 37 Tumor-associated macrophages (TAMs) have been suggested to be involved in accelerating angiogenesis, In addition, LMR had been supposed to reflect the TIL/TAM ratio, as the circulating levels of lymphocytes and monocytes may indicate the formation or the presence of TILs and TAMs, and significant correlation was observed between the LMR and the TIL/TAM ratio. 31 Immunotherapy has emerged as one of the most promising approaches for OC treatment, 40 and change in the LMR has been supposed to be an early surrogate marker of the efficacy of nivolumab monotherapy. 41 Thus, LMR represents the balance between the host's immune status and the degree of tumor progression, and it may therefore be a prognostic biomarker among OC patients.
Subgroup analyses indicated that the favorable prognostic effect of pretreatment LMR for OS was more evident in studies conducted among younger (<55 years) than older patients (≥55 years; P for interaction =0.017), which was further confirmed by meta-regression analysis (P=0.004). One explanation for our finding is that human aging is characterized by a gradual increase in subclinical chronic inflammation, and older people are more likely to get chronic inflammatory diseases. 42 The greater severity of the inflammatory state among older OC patients may weaken the LMR's protective prognostic effect. In addition, older patients responded more efficiently to immunotherapy, such as programmed death-ligand 1 (nivolumab and pembrolizumab), and PD-L1 (atezolizumab) inhibitors also confirmed this finding. 43, 44 Some limitations of this meta-analysis should also be considered. First, between-study heterogeneity was significant for OS (I 2 : 76.5%). Based on subgroup and meta-regression analyses, age was the main source of heterogeneity, and the pooled HR results showed consistent positive relationships. Second, most studies included herein were performed among Asian patients, while only one study examined OS among Caucasian patients, 10 and no relevant studies were found for African patients. Thus, the findings of the present study might be limited to Asian patients, and the prognostic effects of LMR for other populations (eg, Caucasian or African) still need further confirmation. Third, the studies included herein differed in how the covariates were adjusted. However, the pooled estimates were similar between the maximal and minimal numbers of covariate adjustment analyses for both OS and PFS, indicating that these confounders were unlikely to significantly bias our findings (data not shown). Fourth, categorical analysis did not allow detecting the best cutoff point, which invites further studies to solve this problem. Fifth, all included studies were retrospective single-center studies, and the bias was unavoidable.
Conclusion
This meta-analysis demonstrated that higher pretreatment LMR values were associated with more favorable outcomes among OC patients, and the associations were stronger for younger patients than older patients. Future large-scale prospective clinical trials are needed to confirm the LMR's prognostic effect and its cutoff value among OC patients. Therefore, LMR is a readily available, routinely measured, and inexpensive inflammatory biomarker, and if causation and cutoff value of LMR was established, LMR could be easily applied in daily clinical practice. Figure 1 study characteristics 18 For each study, present characteristics for which data were extracted (eg, study size, PiCOs, and follow-up period) and provide the citations 8, Table 1 Risk of bias within studies
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